Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tumour-cell-vaccine-GVAX - Aduro BioTech

Drug Profile

Tumour-cell-vaccine-GVAX - Aduro BioTech

Alternative Names: CG-1940/CG-8711; CG-8123; GVAX Leukemia; GVAX Pancreas; GVAX Prostate

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cell Genesys
  • Developer Aduro BioTech; ANI Pharmaceuticals; BioSante Pharmaceuticals; Cell Genesys; Dana-Farber Cancer Institute; Eli Lilly and Company; Hussman Foundation; Merck Sharp & Dohme; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Cancer vaccines; Gene therapies; Tumour cell vaccines
  • Mechanism of Action Gene transference; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Acute myeloid leukaemia; Pancreatic cancer; Chronic myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Pancreatic cancer
  • Phase I/II Prostate cancer
  • No development reported Breast cancer; Cancer; Chronic myeloid leukaemia; Malignant melanoma; Multiple myeloma
  • Discontinued Non-small cell lung cancer; Renal cancer

Most Recent Events

  • 28 Dec 2018 No recent reports of development identified for phase-I development in Colorectal-cancer in USA (Intradermal, Injection)
  • 01 Jul 2018 Phase-I clinical trials in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (Intradermal) (NCT03153410)
  • 23 Jan 2018 Sidney Kimmel Comprehensive Cancer Center initiates enrolment in a phase II trial for Pancreatic cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (NCT03006302)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top